NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
NAMS Stock Chart & Stats
$29.33
-$0.03(-0.12%)
At close: 4:00 PM EST
$29.33
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$14.06 - $42.00
Previous CloseN/A
Volume118.30K
Average Volume (3M)618.82K
Market Cap
$3.37B
Enterprise Value$3.19B
Total Cash (Recent Filing)$636.24M
Total Debt (Recent Filing)$202.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 07, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding114,975,426
10 Day Avg. Volume673,409
30 Day Avg. Volume618,824
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue141.78
Enterprise Value/Gross Profit142.16
Enterprise Value/Ebitda-13.17
Forecast
1Y Price Target
$49.78Price Target Upside69.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.93
Revenue Forecast (FY)$27.77M
Bulls Say, Bears Say
Bulls Say
Clinical Trial MomentumBlinded event rates in the PREVAIL trial tracking closely with results from the prior BROADWAY study support the potential for similar meaningful reductions in major cardiovascular events.
Financial RunwayManagement indicates a strong cash balance that is sufficient to fund ongoing pivotal trials and a potential U.S. commercial launch, lowering near‑term financing risk.
Regulatory PathwayRegulatory filings accepted in Europe for both monotherapy and a fixed‑dose combination support the prospect of European approval and broader market access for obicetrapib.
Bears Say
Blinded Data InterpretationThe blinded study design limits visibility into unadjudicated events, raising the risk that early favorable trends could be misinterpreted before final adjudication.
Readout Timing UncertaintyUncertainty about when PREVAIL will reach the required event threshold increases the risk of a delayed trial readout and could postpone regulatory filing plans.
Regulatory Submission PlanningAnalysis of PREVAIL event rates may be required before meeting with the FDA, which could complicate timing decisions for an NDA submission and extend regulatory uncertainty.
NewAmsterdam Pharma Company News
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $42.00 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $3.37B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is May 07, 2026 which is in 35 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Feb 18, 2026. The company reported -$0.625 earnings per share for the quarter, missing the consensus estimate of -$0.56 by -$0.065.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.49.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 114,975,426 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.625 in its last earnings report, missing expectations of -$0.56. Following the earnings report the stock price went up 1.476%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.78 (69.72% Upside)
$49.78 (69.72% Upside)
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.58%
12-Months-Change
Fundamentals
Return on Equity
-28.29%
Trailing 12-Months
Asset Growth
-11.03%
Trailing 12-Months
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$49.78
▲(69.72% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Soleno Therapeutics
―
Kiniksa Pharmaceuticals
―
Immunovant
―
Ownership Overview
Currently, No data available
---